Holder evidence
50
SEC ownership of ARS Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001671858.
Lead holder
RA CAPITAL MANAGEMENT, L.P.
13D/G signal
RA CAPITAL MANAGEMENT, L.P.
Latest evidence
31 Mar 2026
- CIK
- 0001671858
- Symbol
- SPRY on Nasdaq
- Location
- San Diego, CA
- SEC evidence mix
- 13D/G, 3/4/5, and 13F
- Lead holder
- RA CAPITAL MANAGEMENT, L.P.
- Latest large-stake holder
- RA CAPITAL MANAGEMENT, L.P.
- Latest evidence date
- 31 Mar 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of ARS Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
RA CAPITAL MANAGEMENT, L.P.
13D/G signal
RA CAPITAL MANAGEMENT, L.P.
Evidence rows
50
Latest as of
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 11%
13D/G row: RA CAPITAL MANAGEMENT, L.P.
Showing 1-8 of 50 holder rows.
Rank 1 holder
RA CAPITAL MANAGEMENT, L.P.
13D/G
3/4/5
13F
- Ownership
- 11%
- Position
- $111.05M
Rank 2 holder
Rubric Capital Management LP
13D/G
13F
- Ownership
- 8.1%
- Position
- $64.4M
Rank 3 holder
James E. Flynn
3/4/5
13D/G
- Ownership
- 7.8%
- Position
- $180.44M
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
11%
|
$111,050,917
10,940,977 shares
|
$0 | 29 Sep 2025 |
| Rubric Capital Management LP |
13D/G
13F
Company
|
8.1%
|
$64,400,000
8,000,000 shares
|
+$14,490,000 | 31 Mar 2026 |
| James E. Flynn |
3/4/5
13D/G
10%+ Owner · Deerfield Management Company, L.P.
|
7.8%
from 13D/G
|
$180,437,416
9,774,508 shares
|
-$13,663,151 | 27 Jun 2025 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
6%
|
$48,748,087
5,916,030 shares
|
+$4,322,622 | 27 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$40,248,399
5,012,254 shares
|
— | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
13F
Company
|
8.4%
|
$66,556,735
8,288,510 shares
|
— | 31 Mar 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
Company
|
7.6%
|
$60,255,610
7,503,812 shares
|
— | 31 Mar 2026 |
| Aberdeen Group plc |
13F
Company
|
4.1%
|
$33,032,345
4,113,617 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$17,439,809.
Buys
$0
Insiders: 0
Sells
$17,439,809
Insiders: 7
Net
-$17,439,809
Shares: -1,070,857
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 1,070,857
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 188,208 | $0 | $1,666,197 | -$1,666,197 |
| 9-12 | 0 | 882,649 | $0 | $15,773,611 | -$15,773,611 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 29 reporting-owner rows connected to ARS Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
29
Lead holder
Sarina Tanimoto
Net 12M change
-$17,439,809
Latest report
02 Jan 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sarina Tanimoto | CHIEF MEDICAL OFFICER, 10%+ Owner | $203,017,758 | -$703,755 | -0.35% | Mixed | 02 Jan 2026 |
| Richard E. Lowenthal | PRESIDENT AND CEO, Director, 10%+ Owner | $202,790,460 | -$724,345 | -0.36% | Mixed | 02 Jan 2026 |
| James E. Flynn | 10%+ Owner | $180,437,416 | -$13,663,151 | -7% | Filing P/S | 27 Jun 2025 |
| Pratik Shah | Director | $44,969,267 | Mixed | 12 Nov 2025 | ||
| Laura Shawver | Director | $2,587,466 | Filing P/S | 25 Jun 2025 | ||
| Alexander A. Fitzpatrick | Chief Legal Officer | $1,263,238 | Filing P/S | 02 Jan 2026 | ||
| Kathleen D. Scott | Chief Financial Officer | $302,017 | -$187,500 | -38% | Mixed | 02 Jan 2026 |
| Jonathan Piazza | Chief Financial Officer | $261,878 | Mixed | 02 May 2022 | ||
| Valerie Odegard | President and CSO | $233,180 | Mixed | 02 May 2022 | ||
| Naomi Hunder | Chief Medical Officer | $205,897 | Mixed | 02 May 2022 | ||
| Jeffrey C. Pepe | Interim CEO and GC | $197,938 | Mixed | 02 Sep 2022 | ||
| Eric Karas | Chief Commercial Officer | $175,259 | -$494,861 | -74% | Filing P/S | 02 Jan 2026 |
| Russ Hawkinson | Sr. Vice President of Finance | $140,921 | Mixed | 02 May 2022 | ||
| Brian Dorsey | Chief Operating Officer | $93,936 | -$190,050 | -67% | Filing P/S | 02 Jan 2026 |
| Justin Chakma | Chief Business Officer | $0 | -$1,476,147 | -100% | Mixed | 02 Jan 2026 |
| Brent L. Saunders | Director | $0 | Mixed | 25 Jun 2025 | ||
| Peter A. Thompson | Director | $0 | Mixed | 25 Jun 2025 | ||
| ORBIMED ADVISORS LLC | Director | $0 | Mixed | 26 Aug 2024 | ||
| Jonathan S. Leff | Director | Mixed | 08 Nov 2022 | |||
| Rajeev Dadoo | Director | Mixed | 25 Jun 2025 |
Recent insider transactions for ARS Pharmaceuticals, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kathleen D. Scott | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Eric Karas | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Alexander A. Fitzpatrick | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Brian Dorsey | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Justin Chakma | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Sarina Tanimoto | SPRY | Stock Option (right to buy) | Award | 875,000 | 875,000 | 02 Jan 2026 | By Spouse | |||
| Sarina Tanimoto | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Richard E. Lowenthal | SPRY | Stock Option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | By Spouse | |||
| Richard E. Lowenthal | SPRY | Stock option (right to buy) | Award | 875,000 | 875,000 | 02 Jan 2026 | Direct | |||
| Brian Dorsey | SPRY | Common Stock | Sale | -66.9% | $190,050 | $8.71 | -21,828 | 10,789 | 13 Nov 2025 | Direct |
| Brian Dorsey | SPRY | Common Stock | Options Exercise | 202.3% | 21,828 | 32,617 | 13 Nov 2025 | Direct | ||
| Brian Dorsey | SPRY | Stock Option (Right to Buy) | Options Exercise | -100% | -21,828 | 0 | 13 Nov 2025 | Direct | ||
| Justin Chakma | SPRY | Common Stock | Sale | -100% | $1,476,147 | $8.87 | -166,380 | 0 | 12 Nov 2025 | Direct |
| Justin Chakma | SPRY | Common Stock | Options Exercise | 22% | 30,000 | 166,380 | 12 Nov 2025 | Direct | ||
| Justin Chakma | SPRY | Stock Option (Right to Buy) | Options Exercise | -25.2% | -30,000 | 89,047 | 12 Nov 2025 | Direct | ||
| Pratik Shah | SPRY | Common Stock | Gift | -7.25% | -350,000 | 4,474,554 | 12 Nov 2025 | By The Pratik Shah Living Trust dated June 15, 2011 | ||
| Richard E. Lowenthal | SPRY | Common Stock | Sale | -4.01% | $724,345 | $14.49 | -50,000 | 1,196,494 | 21 Aug 2025 | By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 |
| Kathleen D. Scott | SPRY | Common Stock | Sale | -55.4% | $187,500 | $15.00 | -12,500 | 10,042 | 21 Aug 2025 | Direct |
| Kathleen D. Scott | SPRY | Common Stock | Options Exercise | 124.5% | 12,500 | 22,542 | 21 Aug 2025 | Direct | ||
| Kathleen D. Scott | SPRY | Stock Option (Right to Buy) | Options Exercise | -1.66% | -12,500 | 739,830 | 21 Aug 2025 | Direct | ||
| Sarina Tanimoto | SPRY | Common Stock | Sale | -2.93% | $530,626 | $14.09 | -37,656 | 1,247,447 | 20 Aug 2025 | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 |
| Sarina Tanimoto | SPRY | Common Stock | Sale | -0.95% | $173,130 | $14.03 | -12,344 | 1,285,103 | 19 Aug 2025 | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 |
| Eric Karas | SPRY | Common Stock | Sale | -59.2% | $254,860 | $16.99 | -15,000 | 10,315 | 01 Jul 2025 | Direct |
| Eric Karas | SPRY | Common Stock | Options Exercise | 145.4% | 15,000 | 25,315 | 01 Jul 2025 | Direct | ||
| Eric Karas | SPRY | Stock Option (Right to Buy) | Options Exercise | -2.68% | -15,000 | 544,588 | 01 Jul 2025 | Direct | ||
| James E. Flynn | SPRY | Class A Common Stock | Sale | -7.04% | $6,831,566 | $18.46 | -370,074 | 4,887,254 | 27 Jun 2025 | Through Deerfield Private Design Fund IV, L.P. |
| James E. Flynn | SPRY | Class A Common Stock | Sale | -7.04% | $6,831,584 | $18.46 | -370,075 | 4,887,254 | 27 Jun 2025 | Through Deerfield Private Design Fund III, L.P. |
| Ra Capital Management, L.P. | SPRY | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | See Footnotes | |||
| Rajeev Dadoo | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Pratik Shah | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Michael Kelly | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Saqib Islam | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Peter A. Thompson | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Brent L. Saunders | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Phillip M. Schneider | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Laura Shawver | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Eric Karas | SPRY | Common Stock | Sale | -66.1% | $240,000 | $16.00 | -15,000 | 7,696 | 18 Jun 2025 | Direct |
| Eric Karas | SPRY | Common Stock | Options Exercise | 194.9% | 15,000 | 22,696 | 18 Jun 2025 | Direct | ||
| Eric Karas | SPRY | Stock Option (Right to Buy) | Options Exercise | -2.61% | -15,000 | 559,588 | 18 Jun 2025 | Direct |
* indicates a reported price that failed the local validity check.